Fundraising Fox

Avisi Technologies

Philadelphia, US · 3 known investors

avisitech.com ↗

Avisi develops VisiPlate, a nanotechnology-enabled implant designed to lower intraocular pressure in patients with open-angle glaucoma. The company is conducting a pivotal clinical trial (SAPPHIRE) to evaluate the device as a minimally-invasive treatment option.

Deep TechHealthtechMedical Devicesin /avisi-technologies@avisi_tech

Founders & leadership

RJ
Rui Jing JiangMs. Jiang is the Chief Executive Officer of the Issuer.
PN
Paul NorrisDirector
BK
Brandon KaoDirector
CM
Catherine MohrDirector
GP
Gary PrudenDirector

Investors · 3

Golden SeedsFlushing · $250K – $2M
Good Growth CapitalCharleston
Life Sciences Greenhouse InvestmentsHarrisburg · $250K – $500K

Reported raises · per SEC filings

Form D private placements
▶$5.3MraisedNov 2022 · 19 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Rui Jing JiangExecutive Officer, Director
  • Paul NorrisDirector
  • Brandon KaoDirector
  • Catherine MohrDirector
  • Gary PrudenDirector
Amount sold
$5.3M
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news